Short-term organ dysfunction is associated with long-term (10-Yr) mortality of septic shock

Critical Care Medicine

Volumn 44, Issue 8, 2016, Pages e728-e736

  Linder, Adam ^a   Lee, Terry ^b   Fisher, Jane ^a   Singer, Joel ^b   Boyd, John ^b   Walley, Keith R ^b   Russell, James A ^b  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

long term survival; organ dysfunction; renal replacement therapy; septic shock; vasopressors; ventilation

Indexed keywords

HYPERTENSIVE FACTOR; VASOCONSTRICTOR AGENT;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; ARTIFICIAL VENTILATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; LIVER DYSFUNCTION; LONG TERM MORTALITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MORTALITY RISK; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SEPTIC SHOCK; SURVIVOR; APACHE; INTENSIVE CARE UNIT; STATISTICS AND NUMERICAL DATA;

APACHE; COMORBIDITY; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MULTIPLE ORGAN FAILURE; RENAL REPLACEMENT THERAPY; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS;

EID: 84978756688     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000001843     Document Type: Article

References (25)

1. Kaukonen KM, Bailey M, Suzuki S, et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014; 311: 1308-1316
2. Linder A, Guh D, Boyd JH, et al. Long-Term (10-year) mortality of younger previously healthy patients with severe sepsis/septic shock is worse than that of patients with nonseptic critical illness and of the general population. Crit Care Med 2014; 42: 2211-2218
3. Linder A, Fjell C, Levin A, et al. Small acute increases in serum creatinine are associated with decreased long-Term survival in the critically ill. Am J Respir Crit Care Med 2014; 189: 1075-1081
4. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709
5. Abraham E, Laterre PF, Garg R, et al; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353: 1332-1341
6. Abraham E, Reinhart K, Opal S, et al; OPTIMIST Trial Study Group: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290: 238-247
7. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome A randomized, controlled, double-blind, multicenter clinical trial. TNF-Alpha MAb Sepsis Study Group. JAMA 1995; 273: 934-941
8. Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836-1843
9. Ranieri VM, Thompson BT, Barie PS, et al; PROWESS-SHOCK Study Group: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366: 2055-2064
10. Opal SM, Laterre PF, Francois B, et al; ACCESS Study Group: Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial. JAMA 2013; 309: 1154-1162
11. Levy MM, Fink MP, Marshall JC, et al; SCCM/ESICM/ACCP/ATS/SIS: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-1256
12. Bernard GR, Wheeler AP, Arons MM, et al A trial of antioxidants N-Acetylcysteine and procysteine in ARDS the Antioxidant in ARDS Study Group. Chest 1997; 112: 164-172
13. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome the Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342: 1301-1308
14. Wheeler AP, Bernard GR, Thompson BT, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network: Pulmonary-Artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354: 2213-2224
15. Sprung CL, Annane D, Keh D, et al; CORTICUS Study Group: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358: 111-124
16. Kaynar AM, Yende S, Zhu L, et al. Effects of intra-Abdominal sepsis on atherosclerosis in mice. Crit Care 2014; 18: 469
17. Yende S, Linde-Zwirble W, Mayr F, et al. Risk of cardiovascular events in survivors of severe sepsis. Am J Respir Crit Care Med 2014; 189: 1065-1074
18. Tate JA, Snitz BE, Alvarez KA, et al; GEM Study Investigators: Infection hospitalization increases risk of dementia in the elderly. Crit Care Med 2014; 42: 1037-1046
19. Cao Z, Yende S, Kellum JA, et al. Proteomics reveals age-related differences in the host immune response to sepsis. J Proteome Res 2014; 13: 422-432
20. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015; 313: 264-274
21. Shah FA, Pike F, Alvarez K, et al. Bidirectional relationship between cognitive function and pneumonia. Am J Respir Crit Care Med 2013; 188: 586-592
22. Yende S, Iwashyna TJ, Angus DC. Interplay between sepsis and chronic health. Trends Mol Med 2014; 20: 234-238
23. Seymour CW, Yende S, Scott MJ, et al. Metabolomics in pneumonia and sepsis: An analysis of the GenIMS cohort study. Intensive Care Med 2013; 39: 1423-1434
24. Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-871
25. Rivers E, Nguyen B, Havstad S, et al; Early Goal-Directed Therapy Collaborative Group: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377